Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Research & Development (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Research & Development for 15 consecutive years, with $64.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 7.74% to $64.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $254.9 million through Dec 2025, up 3.25% year-over-year, with the annual reading at $254.9 million for FY2025, 3.25% up from the prior year.
  • Research & Development hit $64.9 million in Q4 2025 for Corcept Therapeutics, down from $68.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $70.3 million in Q4 2024 to a low of $28.1 million in Q3 2021.
  • Historically, Research & Development has averaged $46.6 million across 5 years, with a median of $44.4 million in 2023.
  • Biggest five-year swings in Research & Development: decreased 17.06% in 2021 and later soared 48.85% in 2023.
  • Year by year, Research & Development stood at $28.5 million in 2021, then increased by 28.88% to $36.8 million in 2022, then skyrocketed by 48.85% to $54.7 million in 2023, then grew by 28.5% to $70.3 million in 2024, then fell by 7.74% to $64.9 million in 2025.
  • Business Quant data shows Research & Development for CORT at $64.9 million in Q4 2025, $68.8 million in Q3 2025, and $60.5 million in Q2 2025.